Role of blood metabolites in mediating the effect of gut microbiome on the mutated-RAS/BRAF metastatic colorectal cancer-specific survival

被引:0
|
作者
Xiang, Yaoxian [1 ]
Zhang, Chan [1 ]
Wang, Jing [1 ]
Cheng, Yurong [1 ]
Wang, Kangjie [1 ]
Wang, Li [1 ]
Tong, Yingying [1 ]
Yan, Dong [1 ]
机构
[1] Capital Med Univ, Beijing Luhe Hosp, Dept Oncol, Beijing 101149, Peoples R China
关键词
Mendelian randomization(MR); Gut microbiome; Metabolites; Mutated-RAS/BRAF metastatic colorectal cancer(M-mCRC); Survival; Causal relationship; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE 1; TRANSFER-RNA SYNTHETASE; MENDELIAN RANDOMIZATION; DIETARY FIBER; CHEMOTHERAPY; BILIRUBIN; BUTYRATE; KRAS; TUMORIGENESIS; INSTRUMENTS;
D O I
10.1007/s00384-024-04686-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundRecent studies have linked alterations in the gut microbiome and metabolic disruptions to the invasive behavior and metastasis of colorectal cancer (CRC), thus affecting patient prognosis. However, the specific relationship among gut microbiome, metabolite profiles, and mutated-RAS/BRAF metastatic colorectal cancer (M-mCRC) remains unclear. Furthermore, the potential mechanisms and prognostic implications of metabolic changes induced by gut microbiome alterations in patients with M-mCRC still need to be better understood.MethodsWe conducted Mendelian randomization (MR) to evaluate the causal relationship of genetically predicted 196 gut microbiome features and 1400 plasma metabolites/metabolite ratios on M-mCRC-specific survival. Additionally, we identified significant gut microbiome-metabolites/metabolite ratio associations based on M-mCRC. Metabolite information was annotated, and functional annotation and pathway enrichment analyses were performed on shared proteins corresponding to significant metabolite ratios, aiming to reveal potential mechanisms by which gut microbiome influences M-mCRC prognosis via modulation of human metabolism.ResultsWe identified 11 gut microbiome features and 49 known metabolites/metabolite ratios correlated with M-mCRC-specific survival. Furthermore, we identified 17 gut microbiome-metabolite/metabolite ratio associations specific to M-mCRC, involving eight lipid metabolites and three bilirubin degradation products. The shared proteins corresponding to significant metabolite ratios were predominantly localized within the integral component of the membrane and exhibited enzymatic activities such as glucuronosyltransferase and UDP-glucuronosyltransferase, crucial in processes such as glucuronidation, bile secretion, and lipid metabolism. Moreover, these proteins were significantly enriched in pathways related to ascorbate and aldarate metabolism, pentose and glucuronate interconversions, steroid hormone biosynthesis, and bile secretion.ConclusionOur study offers novel insights into the potential mechanisms underlying the impact of the gut microbiome on the prognosis of M-mCRC. These findings serve as a meaningful reference for exploring potential therapeutic targets and strategies in the future.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
    Rosati, Gerardo
    Aprile, Giuseppe
    Basile, Debora
    Avallone, Antonio
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [2] Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
    Ottaiano, Alessandro
    Berretta, Massimiliano
    Von Arx, Claudia
    Capozzi, Monica
    Caraglia, Michele
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Progression-free survival in metastatic, BRAF-mutated colorectal cancer
    Morris, Van Karlyle
    Overman, Michael J.
    Maru, Dipen M.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [4] Prognostic effect of specific RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC).
    George, Ben
    Taylor, Bradley W.
    Lasowski, Matthew
    Ritch, Paul S.
    Shreenivas, Aditya Varnam
    Chakrabarti, Sakti
    Kamgar, Mandana
    Zimmermann, Michael T.
    Reddi, Honey, V
    Urrutia, Raul
    Thomas, James P.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
    Hamfjord, Julian
    Guren, Tormod Kyrre
    Glimelius, Bengt
    Sorbye, Halfdan
    Pfeiffer, Per
    Dajani, Olav
    Lingjaerde, Ole Christian
    Tveit, Kjell Magne
    Pallisgaard, Niels
    Spindler, Karen-Lise Garm
    Kure, Elin H.
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (06) : 1385 - 1397
  • [6] Latest Advance to Clinical Development and Future Perspective for RAS/BRAF-mutated Metastatic Colorectal Cancer
    Yoshino, Takayuki
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Role of blood metabolites in mediating the effect of gut microbiota on chronic gastritis
    Liu, Tianying
    Chen, Zhian
    Sun, Li
    Xiong, Lihui
    MICROBIOLOGY SPECTRUM, 2024, 12 (11):
  • [8] Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients
    Pretta, A.
    Persano, M.
    Pinna, G.
    Donisi, C.
    Cimbro, E.
    Parrino, A.
    Migliari, M.
    Dubois, M.
    Mariani, S.
    Liscia, N.
    Lai, E.
    Pusceddu, V.
    Puzzoni, M.
    Ziranu, P.
    Scartozzi, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S142 - S143
  • [9] Prognostic effect of RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC)
    Abid, Haisam
    Szabo, Aniko
    Taylor, Bradley W.
    Shreenivas, Aditya V.
    Chakrabarti, Sakti
    Kamgar, Mandana
    Thomas, James P.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [10] Reclassification of RAS/BRAF allele mutations predicts the survival benefit of triplet chemotherapy in metastatic colorectal cancer
    Zhang, Xiang
    Ma, Haizhong
    He, Yinjun
    He, Wenguang
    Chen, Nan
    Li, Yandong
    Zhong, Weixiang
    Wu, Guosheng
    Zhou, Xile
    Hua, Hanju
    Ye, Feng
    Cai, Hui
    Jiang, Weiqin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16